Your browser is no longer supported. Please, upgrade your browser.
UTHR United Therapeutics Corporation weekly Stock Chart
UTHR [NASD]
United Therapeutics Corporation
Index- P/E8.54 EPS (ttm)12.90 Insider Own0.10% Shs Outstand45.20M Perf Week-6.06%
Market Cap4.98B Forward P/E7.82 EPS next Y14.10 Insider Trans-77.96% Shs Float44.69M Perf Month-2.43%
Income651.60M PEG5.18 EPS next Q3.20 Inst Own94.00% Short Float18.93% Perf Quarter-12.28%
Sales1.47B P/S3.40 EPS this Y102.60% Inst Trans0.08% Short Ratio10.32 Perf Half Y-23.24%
Book/sh37.95 P/B2.90 EPS next Y1.37% ROA43.70% Target Price146.70 Perf Year-35.53%
Cash/sh21.57 P/C5.11 EPS next 5Y1.65% ROE61.70% 52W Range102.50 - 190.13 Perf YTD-29.64%
Dividend- P/FCF14.44 EPS past 5Y46.80% ROI19.10% 52W High-40.65% Beta1.57
Dividend %- Quick Ratio3.40 Sales past 5Y19.80% Gross Margin95.30% 52W Low10.09% ATR4.74
Employees750 Current Ratio3.60 Sales Q/Q12.70% Oper. Margin73.50% RSI (14)46.91 Volatility4.28% 3.34%
OptionableYes Debt/Eq0.00 EPS Q/Q-9.70% Profit Margin61.70% Rel Volume0.80 Prev Close110.19
ShortableYes LT Debt/Eq0.00 EarningsApr 28 BMO Payout0.00% Avg Volume819.54K Price112.84
Recom2.40 SMA20-0.79% SMA50-4.76% SMA200-19.14% Volume456,162 Change2.40%
Apr-29-16Downgrade Ladenburg Thalmann Buy → Neutral
Apr-11-16Reiterated RBC Capital Mkts Sector Perform $150 → $122
Mar-28-16Reiterated Wedbush Outperform $238 → $229
Mar-02-16Reiterated Wedbush Outperform $244 → $238
Feb-10-16Upgrade Standpoint Research Hold → Buy $148
Jul-31-15Reiterated Argus Buy $205 → $200
Jul-29-15Reiterated RBC Capital Mkts Sector Perform $160 → $175
May-27-15Reiterated Argus Buy $195 → $205
Apr-29-15Reiterated RBC Capital Mkts Sector Perform $135 → $160
Mar-12-15Upgrade Argus Hold → Buy $195
Mar-04-15Downgrade Standpoint Research Buy → Hold
Feb-26-15Reiterated H.C. Wainwright Buy $150 → $175
Nov-03-14Downgrade Argus Buy → Hold
Oct-15-14Upgrade Standpoint Research Hold → Buy $144
Aug-29-14Reiterated Standpoint Research Buy $118 → $140
Jul-30-14Reiterated H.C. Wainwright Buy $120 → $150
Apr-07-14Upgrade Standpoint Research Hold → Buy $118
Feb-26-14Reiterated RBC Capital Mkts Sector Perform $80 → $90
Feb-26-14Reiterated Ladenburg Thalmann Buy $138 → $135
Dec-31-13Reiterated Argus Buy $120 → $130
May-03-16 01:04PM  UNITED THERAPEUTICS CORP Financials EDGAR Online Financials
Apr-29-16 11:54AM  United (UTHR) Stock Declines Despite Q1 Earnings Beat Zacks
08:13AM  United Therapeutics downgraded by Ladenburg Thalmann Briefing.com
Apr-28-16 04:48PM  The 52-Week Low Club for Thursday at 24/7 Wall St. -10.91%
12:02PM  What's Behind United Therapeutics' Slumping Shares Today at Motley Fool
11:33AM  Edited Transcript of UTHR earnings conference call or presentation 28-Apr-16 1:00pm GMT Thomson Reuters StreetEvents
11:05AM  Roger Jeffs out in executive shakeup at drugmaker United Therapeutics at American City Business Journals
09:00AM  United Therapeutics Corp Earnings Call scheduled for 9:00 am ET today CCBN
07:07AM  Q1 2016 United Therapeutics Corp Earnings Release - Before Market Open CCBN
06:24AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
06:17AM  United Therapeutics beats 1Q profit forecasts AP
06:12AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
06:05AM  United Therapeutics Corporation Announces Executive Leadership Changes PR Newswire
06:00AM  United Therapeutics Corporation Reports First Quarter 2016 Financial Results PR Newswire
Apr-27-16 06:00AM  United Therapeutics Corporation To Present At Deutsche Bank 41st Annual Health Care Conference PR Newswire
Apr-25-16 08:30AM  SteadyMed Announces Public Availability of PTAB Decision to Institute Inter Partes Review Proceedings GlobeNewswire
Apr-14-16 07:30AM  SteadyMed to Host an Analyst and Investor Reception GlobeNewswire
Apr-11-16 02:20PM  UAB lands $19.5 million grant from biotech giant to start kidney transplant research at bizjournals.com
07:00AM  SteadyMed Announces Initiation of Inter Partes Review Proceedings by U.S. Patent and Trademark Office Against a United Therapeutics Patent GlobeNewswire
Apr-07-16 07:34AM  Financial engineering 'sucking money out of R&D': UTHR CE...
Apr-01-16 02:35PM  United Therapeutics, Supernus sue PTO over patent at bizjournals.com
Mar-30-16 04:03PM  United Therapeutics Has Room to Fall Farther
Mar-28-16 10:50AM  United Therapeutics Tanks, Remodulin Pump Faces Setback
Mar-24-16 03:01PM  Maryland's next big manufacturing industry: Human organs, says Martine Rothblatt at bizjournals.com -10.47%
11:48AM  United Therapeutics Down As FDA Rejects Medtronics Remodulin Pump
06:13AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure
Mar-23-16 08:21AM  United Therapeutics Corp. breached its 50 day moving average in a Bullish Manner : UTHR-US : March 23, 2016
Mar-10-16 01:19PM  United Therapeutics Corp. Value Analysis (NASDAQ:UTHR) : March 10, 2016
Mar-09-16 08:12AM  United Therapeutics Corp. breached its 50 day moving average in a Bearish Manner : UTHR-US : March 9, 2016
08:07AM  How Are IBBs Mid-Caps Faring as of March 7?
Mar-08-16 12:59PM  3 Plays for the Biotech Bear Market (GILD, UTHR) at Investopedia -5.36%
06:00AM  United Therapeutics Corporation To Present At Barclays Global Healthcare Conference PR Newswire
Mar-07-16 06:00AM  The Obsession With Curing Aging Is Now Big Business at Fortune
Mar-02-16 11:15AM  Palo Altos Top Picks for This Year Following Impressive 2015 Returns at Insider Monkey
Mar-01-16 06:40AM  United Therapeutics sees stepped-up competition and says it's 'a good thing' at bizjournals.com
Feb-26-16 04:01PM  United Therapeutics Tops on 4Q Revenues, Earnings Up Y/Y
Feb-25-16 12:32PM  Edited Transcript of UTHR earnings conference call or presentation 25-Feb-16 2:00pm GMT
09:00AM  United Therapeutics Corp Earnings Call scheduled for 9:00 am ET today
07:07AM  Q4 2015 United Therapeutics Corp Earnings Release - Before Market Open
06:39AM  United Therapeutics beats Street 4Q forecasts
06:18AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition
06:12AM  UNITED THERAPEUTICS CORP Files SEC form 10-K, Annual Report
06:00AM  United Therapeutics Corporation Reports 2015 Fourth Quarter And Annual Financial Results PR Newswire
Feb-22-16 08:30AM  Healthcare Booming for Synergy, DepoMed, Novo Nordisk and United Therapeutics Accesswire
Feb-19-16 06:03AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Other Events
Feb-18-16 08:30PM  United Therapeutics Corporation To Announce Fourth Quarter And Annual 2015 Financial Results Before Market Open On Thursday, February 25, 2016 PR Newswire
08:00PM  United Therapeutics Receives Paragraph IV Notice Letter For Orenitram PR Newswire
Feb-03-16 09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Mylan, United Therapeutics and INSYS Therapeutics
Feb-02-16 10:46AM  4 Top-Ranked Biotech Stocks on Sale
Feb-01-16 06:13AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material De
Jan-19-16 03:22PM  United Therapeutics settles patent dispute with Teva Pharmaceuticals at bizjournals.com
09:30AM  The Zacks Analyst Blog Highlights: Aerie Pharmaceuticals, United Therapeutics, Pacira Pharmaceuticals, Ohr Pharmaceutical and Infinity Pharmaceuticals
06:05AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Other Events
Jan-07-16 04:50PM  Cardiome/SteadyMed's PAH Drug Approved for Review in EU
Jan-06-16 11:24AM  United Therapeutics Corp. Value Analysis (NASDAQ:UTHR) : January 6, 2016
08:11AM  United Therapeutics Corp. breached its 50 day moving average in a Bearish Manner : January 6, 2016
06:00AM  United Therapeutics Corporation To Present At 34th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-31-15 12:44PM  Rockville biotech preps for trials after getting rare pediatric drug status at bizjournals.com
Dec-28-15 07:13PM  New IBD 50 Tech Stocks: LinkedIn Not The Only Network at Investor's Business Daily
Dec-23-15 09:09AM  8 Biotech Stocks That Should Be in Your Portfolio Right Now at TheStreet
Dec-08-15 11:45AM  Moogfest headliners announced for 2016 Durham debut at bizjournals.com
Dec-07-15 07:00AM  SteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associated With Trevyent Compared to Remodulin GlobeNewswire
Dec-01-15 04:03PM  Top Stock Picks of Multi-Billion Dollar, Healthcare-Focused Fund Palo Alto Investors at Insider Monkey
10:31AM  Hedge Funds Are Selling YPF SA (ADR) (YPF) at Insider Monkey
Nov-24-15 11:03AM  How Smart Money Is Trading United Therapeutics Corporation (UTHR) at Insider Monkey
Nov-21-15 03:03PM  United Therapeutics' Stock Picked Up Steam in October: Time to Buy? at Motley Fool
Nov-11-15 06:04AM  United Therapeutics Stock: What is the Social Media Crowd Thinking About UTHR? -5.16%
Nov-06-15 10:17AM  An Overview of QUALs Holdings
Nov-02-15 05:00PM  United Therapeutics Led the Biotechnology Subgroup for the Week
12:58AM  Drug Makers Buy Pricey Vouchers to Speed Products to Market at The Wall Street Journal
Nov-01-15 08:31PM  Drug Makers Buy Pricey Vouchers to Speed Products to Market at The Wall Street Journal
Oct-30-15 09:44AM  United Therapeutics Corp. breached its 50 day moving average in a Bullish Manner : October 30, 2015
Oct-28-15 12:18PM  United Therapeutics Beats on Q3 Earnings, Revenues
08:45AM  United Therapeutics (UTHR) Catches Eye: Stock Jumps 8.8%
Oct-27-15 04:23PM  Edited Transcript of UTHR earnings conference call or presentation 27-Oct-15 1:00pm GMT +8.78%
07:07AM  Q3 2015 United Therapeutics Corp Earnings Release - Before Market Open
06:15AM  United Therapeutics tops Street 3Q forecasts
06:09AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition
06:09AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report
06:00AM  United Therapeutics Corporation Reports Third Quarter 2015 Financial Results PR Newswire
Oct-21-15 07:00AM  SteadyMed Files Inter Partes Review to Invalidate United Therapeutics Patent GlobeNewswire
06:00AM  United Therapeutics Corporation To Announce Third Quarter 2015 Financial Results Before Market Open On Tuesday, October 27, 2015 PR Newswire
Oct-20-15 01:16PM  Drug companies are paying huge sums to fast-track FDA approval at Fortune
Oct-15-15 05:34PM  Winnebago, United Therapeutics Lead Payout Hikes at Investor's Business Daily
06:07AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure
06:00AM  United Therapeutics Announces Additional $500 Million Share Repurchase Program PR Newswire
Oct-02-15 05:20AM  What LinkedIn can tell us about filling open jobs (Video) at bizjournals.com
Oct-01-15 11:04AM  United Therapeutics Corp. Earnings Q2, 2015
Sep-30-15 06:08AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement
06:00AM  United Therapeutics Announces Settlement of Patent Litigation with Sandoz Inc. PR Newswire
Sep-29-15 11:25AM  Independent Research Sees 3 Top Health and Biotech Stocks as Oversold at 24/7 Wall St.
Sep-25-15 10:06AM  Alnylam and United Therapeutics: Worst Performers of Mid-Cap
Sep-24-15 05:02PM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets
Sep-22-15 04:30PM  Synthetic Genomics Inc. Expands Collaborative Research and Development Agreement with Lung Biotechnology PBC, a Subsidiary of United Therapeutics Corporation, to Develop Organs for Transplantation PR Newswire
11:06AM  IBB Mid-Cap Outperforms XBI Mid-Cap
Sep-11-15 04:57PM  United Therapeutics Corporation's Stock Slumped in August: Is It Now a Bargain? at Motley Fool
Sep-02-15 01:15PM  Chip, Biotech ETFs, Gutted In August, Lead Relief Rally at Investor's Business Daily +6.32%
Aug-27-15 12:55PM  CEO pay surged last year after stock-market gains, pension changes at MarketWatch
Aug-20-15 04:35PM  United Therapeutics to Sell Priority Review Voucher to AbbVie
12:09AM  Investors Should Review AbbVie Deal as a Priority at The Wall Street Journal
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's principal therapeutic products and product candidates include Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH); Tyvaso, an inhaled prostacyclin therapy for PAH; Adcirca, a once-daily oral therapy for PAH; Orenitram, a prostacyclin analog for PAH; Unituxin, an antibody that binds to cancerous tumors and destroys the cancer cells; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROTHBLATT MARTINE AChairman & Co-CEOApr 28Option Exercise30.755,547170,5705,787Apr 29 04:06 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 28Sale106.815,547592,499240Apr 29 04:06 PM
MAHON PAUL AEVP & General CounselApr 21Option Exercise47.506,000285,00041,221Apr 25 04:13 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 21Option Exercise30.755,546170,5405,786Apr 25 04:14 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 21Sale115.745,546641,922240Apr 25 04:14 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 14Option Exercise30.755,547170,5705,787Apr 18 04:24 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 14Sale114.325,547634,116240Apr 18 04:24 PM
MAHON PAUL AEVP & General CounselApr 07Option Exercise47.506,000285,00041,221Apr 08 05:14 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 07Option Exercise30.755,546170,5405,786Apr 08 05:14 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 07Sale113.315,546628,420240Apr 08 05:14 PM
CAUSEY CHRISTOPHERDirectorApr 01Option Exercise51.7775038,8281,708Apr 04 04:11 PM
DWEK RAYMONDDirectorApr 01Option Exercise41.143,000123,4203,000Apr 04 04:12 PM
DWEK RAYMONDDirectorApr 01Sale110.813,000332,4280Apr 04 04:12 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 24Option Exercise30.755,546170,5405,786Mar 28 04:13 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 24Sale110.805,546614,500240Mar 28 04:13 PM
MAHON PAUL AEVP & General CounselMar 17Option Exercise47.506,000285,00041,221Mar 18 04:09 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 17Option Exercise30.755,547170,5705,787Mar 18 04:08 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 17Sale118.225,547655,769240Mar 18 04:08 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 10Option Exercise30.755,546170,5405,786Mar 11 04:00 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 10Sale123.415,546684,446240Mar 11 04:00 PM
CAUSEY CHRISTOPHERDirectorMar 03Option Exercise51.7775038,8281,708Mar 04 04:58 PM
DWEK RAYMONDDirectorMar 03Option Exercise41.143,000123,4203,000Mar 04 05:00 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 03Option Exercise30.755,547170,5705,787Mar 04 04:59 PM
MAHON PAUL AEVP & General CounselMar 03Option Exercise50.096,000300,54041,054Mar 04 04:57 PM
PATUSKY CHRISTOPHERDirectorMar 03Option Exercise48.113,000144,3303,000Mar 04 04:59 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 03Sale126.785,547703,276240Mar 04 04:59 PM
Thompson Tommy GDirectorMar 01Option Exercise48.113,000144,3303,000Mar 03 10:06 AM
Thompson Tommy GDirectorMar 01Sale126.543,000379,6200Mar 03 10:06 AM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 25Option Exercise30.755,546170,5405,786Feb 26 05:31 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 25Sale122.455,546679,104240Feb 26 05:31 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 18Option Exercise30.755,547170,5705,787Feb 22 05:34 PM
MAHON PAUL AEVP & General CounselFeb 18Option Exercise50.096,000300,54041,054Feb 22 05:33 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 18Sale128.265,547711,435240Feb 22 05:34 PM
JEFFS ROGERPresident & Co-CEOFeb 12Option Exercise65.809,000592,2009,559Feb 17 04:10 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 11Option Exercise30.755,546170,5405,786Feb 16 08:07 AM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 11Sale120.475,546668,139240Feb 16 08:07 AM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 04Option Exercise30.755,547170,5705,787Feb 08 08:09 AM
MAHON PAUL AEVP & General CounselFeb 04Option Exercise49.826,000298,92141,054Feb 08 04:48 PM
CAUSEY CHRISTOPHERDirectorFeb 04Option Exercise51.7775038,8281,708Feb 08 04:49 PM
DWEK RAYMONDDirectorFeb 04Option Exercise41.143,000123,4203,000Feb 04 04:21 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 04Sale122.135,547677,459240Feb 08 08:09 AM
DWEK RAYMONDDirectorFeb 04Sale122.663,000367,9860Feb 04 04:21 PM
JEFFS ROGERPresident & Co-CEOJan 27Option Exercise65.803,000197,4003,559Jan 28 05:03 PM
JEFFS ROGERPresident & Co-CEOJan 22Option Exercise65.803,000197,4003,559Jan 26 04:12 PM
MAHON PAUL AEVP & General CounselJan 21Option Exercise47.506,000285,00041,054Jan 22 07:48 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 21Option Exercise30.755,547170,5705,787Jan 22 07:48 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 21Sale127.005,547704,444240Jan 22 07:48 PM
JEFFS ROGERPresident & Co-CEOJan 20Option Exercise65.803,000197,4003,559Jan 21 04:26 PM
JEFFS ROGERPresident & Co-CEOJan 15Option Exercise65.803,000197,4003,559Jan 20 07:08 AM
ROTHBLATT MARTINE AChairman & Co-CEOJan 14Option Exercise30.755,546170,5405,786Jan 19 12:16 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 14Sale135.945,546753,900240Jan 19 12:16 PM
JEFFS ROGERPresident & Co-CEOJan 13Option Exercise65.803,000197,4003,559Jan 14 04:51 PM
JEFFS ROGERPresident & Co-CEOJan 08Option Exercise65.804,000263,2004,559Jan 11 04:32 PM
DWEK RAYMONDDirectorJan 07Option Exercise41.143,000123,4203,000Jan 07 04:51 PM
PATUSKY CHRISTOPHERDirectorJan 07Option Exercise48.113,000144,3303,000Jan 08 04:43 PM
CAUSEY CHRISTOPHERDirectorJan 07Option Exercise49.332,250110,9932,458Jan 08 04:44 PM
MAHON PAUL AEVP & General CounselJan 07Option Exercise47.506,000285,00041,054Jan 08 04:44 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 07Option Exercise30.755,547170,5705,787Jan 08 04:46 PM
DWEK RAYMONDDirectorJan 07Sale143.753,000431,2550Jan 07 04:51 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 07Sale145.845,547808,973240Jan 08 04:46 PM
JEFFS ROGERPresident & Co-CEOJan 06Option Exercise65.804,000263,2004,559Jan 07 04:53 PM
JEFFS ROGERPresident & Co-CEOJan 04Option Exercise65.805,000329,0005,559Jan 05 04:44 PM
ROTHBLATT MARTINE AChairman & Co-CEODec 31Option Exercise30.755,546170,5405,786Jan 04 04:15 PM
JEFFS ROGERPresident & Co-CEODec 30Option Exercise65.805,000329,0005,559Dec 31 12:00 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerDec 29Option Exercise65.802,000131,6003,375Dec 30 04:02 PM
JEFFS ROGERPresident & Co-CEODec 28Option Exercise65.805,000329,0005,559Dec 30 04:03 PM
ROTHBLATT MARTINE AChairman & Co-CEODec 24Option Exercise30.755,546170,5405,786Dec 28 04:37 PM
ROTHBLATT MARTINE AChairman & Co-CEODec 24Sale159.585,546885,030240Dec 28 04:37 PM
JEFFS ROGERPresident & Co-CEODec 23Option Exercise65.805,000329,0005,559Dec 28 08:01 AM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerDec 22Option Exercise65.802,000131,6003,375Dec 23 04:05 PM
JEFFS ROGERPresident & Co-CEODec 18Option Exercise65.805,000329,0005,559Dec 21 04:07 PM
MAHON PAUL AEVP & General CounselDec 17Option Exercise47.506,000285,00041,054Dec 21 04:07 PM
ROTHBLATT MARTINE AChairman & Co-CEODec 17Option Exercise30.755,546170,5405,786Dec 18 04:22 PM
ROTHBLATT MARTINE AChairman & Co-CEODec 17Sale158.495,546878,982240Dec 18 04:22 PM
JEFFS ROGERPresident & Co-CEODec 16Option Exercise65.805,000329,0005,559Dec 17 04:04 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerDec 15Option Exercise65.802,000131,6003,375Dec 16 04:49 PM
JEFFS ROGERPresident & Co-CEODec 11Option Exercise65.804,000263,2004,559Dec 14 04:07 PM
ROTHBLATT MARTINE AChairman & Co-CEODec 10Option Exercise30.755,546170,5405,786Dec 11 04:03 PM
ROTHBLATT MARTINE AChairman & Co-CEODec 10Sale154.495,546856,825240Dec 11 04:03 PM
JEFFS ROGERPresident & Co-CEODec 09Option Exercise65.804,000263,2004,559Dec 10 04:42 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerDec 08Option Exercise65.802,000131,6003,375Dec 10 04:43 PM
JEFFS ROGERPresident & Co-CEODec 04Option Exercise65.805,000329,0005,559Dec 08 03:05 PM
DWEK RAYMONDDirectorDec 03Option Exercise41.143,000123,4203,000Dec 03 04:10 PM
CAUSEY CHRISTOPHERDirectorDec 03Option Exercise48.111,50072,1652,458Dec 04 04:20 PM
MAHON PAUL AEVP & General CounselDec 03Option Exercise47.506,000285,00041,054Dec 04 04:21 PM
DWEK RAYMONDDirectorDec 03Sale157.223,000471,6700Dec 03 04:10 PM
JEFFS ROGERPresident & Co-CEODec 02Option Exercise65.805,000329,0005,559Dec 03 04:11 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerDec 01Option Exercise65.802,000131,6003,375Dec 02 04:07 PM
JEFFS ROGERPresident & Co-CEONov 27Option Exercise65.804,000263,2004,559Nov 30 04:15 PM
ROTHBLATT MARTINE AChairman & Co-CEONov 27Option Exercise30.765,561171,0585,786Nov 30 04:14 PM
ROTHBLATT MARTINE AChairman & Co-CEONov 27Sale153.815,561855,340240Nov 30 04:14 PM
JEFFS ROGERPresident & Co-CEONov 25Option Exercise64.385,000321,8904,059Nov 30 04:15 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerNov 24Option Exercise63.432,000126,8602,375Nov 25 02:34 PM
JEFFS ROGERPresident & Co-CEONov 20Option Exercise61.064,000244,2404,559Nov 24 04:02 PM
ROTHBLATT MARTINE AChairman & Co-CEONov 19Option Exercise32.379,661312,7545,786Nov 20 04:09 PM
MAHON PAUL AEVP & General CounselNov 19Option Exercise47.506,000285,00041,054Nov 20 04:41 PM
ROTHBLATT MARTINE AChairman & Co-CEONov 19Sale148.569,6611,435,267240Nov 20 04:09 PM
JEFFS ROGERPresident & Co-CEONov 18Option Exercise61.064,000244,2404,559Nov 20 04:10 PM
JEFFS ROGERPresident & Co-CEONov 13Option Exercise61.064,000244,2404,559Nov 17 08:03 AM
ROTHBLATT MARTINE AChairman & Co-CEONov 12Option Exercise30.755,546170,5405,786Nov 13 04:05 PM